Abstract
Diffuse large B cell lymphoma is the most common subtype of non-hodgkin lymphoma in adults. This disease usually presents with systemic symptoms, fast growing nodal or extra-nodal lesions. Most commonly involved lymph nodes are cervical while extra nodal involvement usually affects the gastrointestinal system. Within the gastrointestinal system the stomach is usually the first organ to be affected. Pancreatic involvement, however is very rare in patients with lymphoma.
Keywords
References
- 1. Dong, A., Dong, H., Zhang, L., & Zuo, C. (2013). Hypermetabolic lesions of the pancreas on FDG PET/CT. Clinical nuclear medicine, 38(9), e354–e366. https://doi.org/10.1097/RLU.0b013e3182708503
- 2. Dong, A., Cui, Y., Gao, L., Wang, Y., Zuo, C., & Yang, J. (2014). Patterns of FDG uptake in pancreatic non-Hodgkin's lymphoma lesions. Abdominal imaging, 39(1), 175–186. https://doi.org/10.1007/s00261-013-0041-5
- 3. Saif, M. W., Khubchandani, S., & Walczak, M. (2007). Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. World journal of gastroenterology, 13(36), 4909–4911. https://doi.org/10.3748/wjg.v13.i36.4909
- 4. Benameur, Y., Nabih, S. O., Sahel, O. A., & Doudouh, A. (2025). Pancreatic Involvement in Follicular Lymphoma Detected on 18FDG-PET/CT. Molecular imaging and radionuclide therapy, 34(2), 132–134. https://doi.org/10.4274/mirt.galenos.2024.
Details
| Primary Language | English |
|---|---|
| Subjects | Nuclear Medicine |
| Journal Section | Image Presentation |
| Authors | |
| Submission Date | December 26, 2025 |
| Acceptance Date | January 8, 2026 |
| Publication Date | January 9, 2026 |
| Published in Issue | Year 2026 Issue: 1 |
Cite
Aim & Scope
The journal covers the articles about the included fields and will focus on innovations and new developments. All the articles about Imaging in Oncology will be accepted in case of including new advances.
The main topic of this journal is Oncologic Imaging and the journal will accept articles (original, case reports as well as review articles) in all the fields (Nuclear Medicine, Radiation Oncology and Radiology) about Oncologic Imaging.
The journal covers the articles about the included fields and will focus on innovations and new developments. All the articles about Imaging in Oncology will be accepted in case of including new advances.
The main topic of this journal is Oncologic Imaging and the journal will accept articles (original, case reports as well as review articles) in all the fields (Nuclear Medicine, Radiation Oncology and Radiology) about Oncologic Imaging.
Author Guidelines
Template
Cambria, 9 font size. Abstract should be at most 200 words. Key words that will consist of at least 3 and maximum 5 words should be written on the left side. Mathematical expressions should not be included in essence.
Content should be written in 1 column with Cambria 10 font size. The first line of each paragraph should be written by 0.5 cm indentation.
The article should begin with an introduction section, which includes the ideas and the basic objectives and approaches of the article, combining scientific knowledge, evidence-based information and logical discussions in different disciplines. This section should be written considering all readers. Technical terms, symbols and abbreviations should be defined when first used in the article.
The main sections of the manuscript are “introduction”, “method” “results” “discussion” and “conclusion” and they should be written in 10 font size, justify, bold and capital letters.
All of the empty lines should have 8 font size.
This template explains how to design the manuscript. If the author (s) uses this template file, no settings change will be required since settings such as font and size, line spacing, spaces before paragraphs, indents, etc. are made in styles. If you want to avoid problems when copy and paste texts or with the text format, you can use “Applying styles to the article” section which is at the end of template.
Ethical Principles and Publication Policy
Ethical Principles and Publication Policy
Use of Generative AI
MOI accepts "2023 STM guidelines" for use of AI in publications.
PUBLICATION ETHICS AND MALPRACTICE STATEMENT
Molecular Oncologic Imaging (MOI) follows certain ethical standards for publication, existing to ensure high-quality scientific publications, public trust in scientific findings, and due credit for original ideas. MOI is connected to the Committee on Publication Ethics (COPE), abides by its Code of Conduct, and aims to adhere to its Best Practice Guidelines.
Committee on Publication Ethics (COPE). (2011, March 7). Code of Conduct and Best-Practice Guidelines for Journal Editors. Retrieved from http://publicationethics.org/files/Code%20of%20Conduct_2.pdf
Authors who submit papers to MOI certify that his or her work is original and is not published or under publication consideration elsewhere. In addition, authors confirm that submitted papers have not been copied or plagiarized, in whole or in part, from other papers or studies. Authors certify that he or she does not have potential conflicts of interest or partial benefits associated with his or her papers.
MOI will check for plagiarism in all submitted articles prior to publication. If plagiarism is detected at any stage of the publication process, the author will be instructed to rewrite the manuscript. Every submission will be scanned by iThenticate® to prevent plagiarism. If any manuscript is 20% plagiarized the article will be rejected and the author will be notified. We strongly recommend that authors check paper content before submitting for publication. Plagiarism can be checked by using free online software, like (FREE PLAGARISM CHECKER at http://www.quetext.com/.)
MOI is committed to objective and fair blind peer reviews of submitted papers and the prevention of any actual or potential conflicts of interest between writers and reviewers.
Submitting authors must confirm the following:
1. Manuscripts must be the original work of the submitting author.
2. Submitted manuscripts must be unpublished.
3. There should be no conflict of interest. If it exists, it must be clearly stated.
4. Authors should cite all data sources used in the preparation of the manuscript.
Please note: It is unethical to submit a manuscript to more than one journal concurrently.
Reviewers must confirm the following:
1. Manuscripts are reviewed fairly based on the intellectual content of the paper regardless of gender, race, ethnicity, religion, citizenship or political view of the author(s).
2. Any observed conflict of interest during the review process must be sent to the editor.
3. Information pertaining to the manuscript is kept confidential.
4. Information that may be a cause for rejection of publication must be sent to the editor.
Editors must confirm the following:
1. Manuscripts are reviewed fairly based on the intellectual content of the paper regardless of gender, race, ethnicity, religion, citizenship or political view of the author(s.)
2. Information pertaining to manuscripts is kept confidential.
3. Any observed conflict of interest pertaining manuscripts must be disclosed.
Please note: The Editorial Board takes responsibility for making publication decisions on submitted manuscripts based on the reviewer’s evaluation of the manuscript, policies of the journal editorial board, and legal efforts to prevent plagiarism, libel, and copyright infringement
Note: Author should make corrections in 2 months, otherwise paper will rejected.
Peer Review Policy
The author(s) of the present study and the article accept(s) the ethical responsibilities that fit the PUBLICATION ETHICS. Each author is responsible for the content of his or her article. Articles submitted for publication are checked by the iThenticate ® (Professional Plagiarism Prevention) program. If an article contains plagiarism or self-plagiarism in more than 20% of the manuscript, it will be returned to the author for appropriate citation and correction.
· Submission of the same manuscript to different journals will not be accepted.
· Submissions with contents outside the scope of MOI will not be considered for review.
· Submissions will have a double-blind peer review.
· All papers are expected to have original content. They should not have been previously published or under review.
· The journal requires a minimum of three independent referees. All submissions are subject to a double-blind peer review.
· Publication decisions are made by the journal's Editor-in-Chief on the basis of the referees' reports.
· Submitted papers and referee reports are archived whether they are published or not and are not returned.
· Authors who want to discontinue the publication process after submission to MOI have to apply to the editorial board in a written correspondence.
· Authors are responsible for the writing quality of his or her papers.
· MOI is FREE of charge and will not pay any copyright fee to authors.
Open Access Copyright Policy
Open access (OA) journals are scholarly journals that are available online "without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.” Open Access (OA) provides unlimited access and reuseability of research publications online for free. Therefore, the open access therefore creates the network for reaching the widest possible audience, sharing the entire papers and building upon them.
MOI has signed the Budapest Open Access Initiative and shows its “openness” clearly in a standardized form.
MOI also supports the Budapest Open Access Initiative definition of ''Open Access,'' which is defined as:
“Its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.”
Articles published in MOI will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License
MOI is licenced by Creative Commons Attribution-ShareAlike 4.0 International License.
https://creativecommons.org/licenses/by-sa/4.0/ You can find information about CC-BY-SA please click https://creativecommons.org/licenses/by-sa/4.0/legalcode
The auhtor(s) retain all copyrights of their articles. However, authors grant the publisher non-exclusive publishing rights to publish the articles.
Archieving Policy (LOCKSS)
The LOCKSS system has permission to collect, preserve, and serve this Archival Unit.
The MOI is using the LOCKKS archiving system.
The LOCKSS Program, based on the program used at Stanford University Libraries, provides libraries and publishers with award-winning, low-cost, open source digital preservation tools to preserve and provide access to persistent and authoritative digital content.
The LOCKSS Program (https://www.lockss.org/) is an open-source, library-led digital preservation system built on the principle that “lots of copies keep stuff safe.” The LOCKSS Program develops and supports libraries using an open source peer-to-peer digital preservation software.
The LOCKSS system allows librarians to access to the e-content to which they subscribe, restoring the print purchase model with which librarians are familiar.
The Global LOCKSS Network preserves today's e-journals and e-books for tomorrow's readers. The Global LOCKSS Network is a proven preservation approach that uniquely empowers both libraries and publishers. It enhances a library's value by restoring library collections via a locally installed "LOCKSS box", which is essentially a digital bookshelf. The Global LOCKSS Network enhances a publisher's value by preserving the original published artifact, including branding, historical context, and underlying files. It protects the publisher's interest by driving all reader traffic to their web site. The Global LOCKSS Network is administered and managed by the Stanford University Libraries LOCKSS Program. See the LOCKSS Program website for additional information, http://www.lockss.org/lockss/Home.
A detailed explanation of what sets the LOCKSS software apart and how preservation works in the LOCKSS network (e.g. technical infrastructure, security) can be found in the following link: https://www.lockss.org/about/how-it-works/.
Complaint Policy
Complaints are welcome as they provide an opportunity for improvement. Responses to complaints should be quick, helpful, and constructive. Please address complaints with a volume number, issue number, paper ID, paper title, and page number.
MOI accepts the following complaints:
· Authorship complaints
· Plagiarism complaints
· Multiple, duplicate, and concurrent publications or simultaneous submissions
· Allegations of research errors and fraud
· Research standards violations
· Undisclosed conflicts of interest
· Reviewer bias or competitive/harmful acts by reviewers
Policy for Handling Complaints
If the Journal receives a complaint that any contribution to the Journal infringes intellectual property rights or contains material inaccuracies, libelous materials, or otherwise unlawful materials, the Journal will investigate the complaint. An investigation may include a request that the parties involved substantiate their claims (the Journal will make a good faith determination whether to remove the allegedly wrongful material). A decision not to remove material should represent the Journal's belief that the complaint is without sufficient foundation, or if well‐founded, that a legal defense or exemption may apply. The Journal will document its investigation and decision. We strive to ensure that MOI is of the highest quality and is free from errors. However, we accept that occasionally mistakes might happen.
Editorial Complaints Policy
The Managing Editor and staff of MOI will make every endeavor to resolve issues as soon as possible in the most appropriate way, offering a right of reply when necessary. We will investigate complaints in a blame-free manner, looking to see how systems can be improved to prevent mistakes occurring.
Guiding Principles
Our general approach to complaints is that they are a rare but inevitable part of a process that involves putting together complex material at great speed. Despite rare mistakes, we will spend effort to treat complaints with urgency. Timely solutions can prevent the escalation of problems. All substantial errors and complaints are referred to senior executives within the editorial staff.
The procedure outlined below aims to be fair to the submitting authors who have complaints as well asthe things they complain about. All complaints will be acknowledged within three working days if by email. If possible, a definitive response will be made within two weeks. If impossible, an interim response will be given within two weeks. Interim responses will be provided until the complaint is resolved. Escalated complaints are sent to the editor.
How to Make a Complaint
Complaints about editorial content should be made as soon as possible after publication, preferably by email to: zehrapinarkoc@gmail.com
Article Correction Policy
The online, published version of an article is considered the final and complete version. Even though it is possible to correct this version, our policy (in common with other publishers) is not to do so, except in very rare circumstances.
The only typographical errors that can be corrected are: author names, affiliations, article titles, abstracts, and keywords. In such cases, an erratum or corrigendum would be necessary as well (see below) so that there is a record of the difference between the online and print versions.
We can publish a correction to your article if there is a serious error, for example with regard to scientific accuracy, or if your reputation or that of the journal would be affected. We do not publish corrections that do not affect the contribution in a material way or significantly impair the reader’s understanding of the contribution (such as a spelling mistake or a grammatical error).
Please send an email to "zehrapinarkoc@gmail.com" in the event a correction is needed.
Errata
An erratum will be used if an important error has been found during the publication process of the journal article. Errors requiring an erratum include: an error that affects the publication record, the scientific integrity of the paper, the reputation of the authors or of the journal, and errors of omission (e.g. failure to make factual proof corrections requested by authors within the deadline provided by the journal and within journal policy).
Erratas are not published for typing errors except where an error is significant (for example, an incorrect unit.) A significant error in a figure or table is corrected by the publication of a newly- corrected figure or table as an erratum. The figure or table is republished only if the editor considers it necessary.
Corrigenda
A corrigendum is a notification of a significant error made by the authors of the article. All authors must sign a corrigenda that is submitted for publication.
In cases where co-authors disagree, the editors will take advice from independent peer-reviewers and impose the appropriate amendment; noting the dissenting author(s) in the text of the published version.
Addenda
An addendum is a notification of a peer-reviewed addition of information to a paper. An example is a response to a reader’s request for clarification. Addenda do not contradict the original publication. If the author inadvertently omits significant information, the information can be published as an addendum after peer review.
Addenda are published only rarely and only when the editors decide that the addendum is crucial to the reader’s understanding of a significant part of the published contribution.
Price Policy
Indexes
Other Indexes
Journal Boards
Editor
Zehra Pınar KOç
Title : Professor
Department : Faculty of Medicine / Department of Nuclear Medicine
Place of birth : KONYA
Business Address :
Phone : +90-324-2410000
Fax : +90-324-2410098
e-Mail : pinarkoc@mersin.edu.tr
zehrapinarkoc@gmail.com
URL : http://apbs.mersin.edu.tr/pinarkoc
Researcher ID :
Scopus ID :
Orcid ID :
Scholar ID :
h-index :
publons_id :
Point : 29863
Foreign Language : English, iyi, ÜDS, 87
Created : 2015-07-04 07:23:28
Last Modification : 2019-02-11 13:53:16
Academic Degrees
Degree Department/Program Institute Year
MD MEDICAL SCHOOL ANKARA UNIVERSITY 2003
PHYSICIAN NUCLEAR MEDICINE AKDENIZ UNIVERSITY 2008
Theses
Expertise in Medicine Thesis
1. The place of combining ischemia modified albumin (IMA) levels to myocardial perfusion scintigraphy in diagnosis of coronary artery disease.,
Supervisor: Dr. Metin Erkılıç, Akdeniz University, Others, Other Department, Antalya, Turkey, .
Positions Held
Title Institute Year
ASSOC. PROF. DR FIRAT UNIVERSITY 2011-11-11 - 2014-01-27
ASSIST. PROF. DR FIRAT UNIVERSITY 2014-01-28 - 2014-12-30
PROF DR MERSIN UNIVERSITY 2015-01-09 - Continue
Administrative Duties
Title Dutie Institution/Other Year
HEAD OF RADIATION PROTECTION
COMMITTEE
MANAGEMENT OF RADIATION PROTECTION
COMMITTEE
MERSIN UNIVERSITY 2018-07-17 - 2018-12-26
HEAD OF DEPARTMENT HEAD OF DEPARTMENT FIRAT UNIVERSITY 2011-11-30 - 2014-11-30
Co-Editor
Editorial Board
Yıldız Teknik Üniversitesi Biyomühendislik bölümünde Doktora eğitimi almaktayım. Yıldız Teknik Üniversitesi Biyomühendislik bölümünden, çift lisansım olan Moleküler Biyoloji ve Genetik bölümünden ve Anadolu Üniversitesi Sağlık Kurumları İşletmeciliği bölümünden mezun oldum. Ayrıca Yıldız Teknik Üniversitesi Biyomühendislik bölümünde yüksek lisans eğitimimi tamamladım. Yüksek lisans tezimde meme kanserine karşı hibridoma teknolojisine dayalı poliklonal antikor üretimi üzerine çalışmalar yaptım.
Eğitimim sırasında Florence Nightingale Hastanesi biyokimya laboratuvarında ve Bıçakçılar Tıbbi cihazlar A.Ş de tek kullanımlık üretim bölümünde ve Bezmi ALEM Vakıf Üniversitesi Yaşam Bilimleri ve Biyoteknoloji Enstitüsünde rekombinant protein üzerine staj yaptım. Yüksek lisans eğitimim sürecinde hücre kültürü ve doku mühendisliği laboratuvarında hücre kültürü eğitimi (kök hücreleri, kanser hücreleri (MCF-7, AU-595, MDA-MB-231, AGS), immün sistem hücreleri, epitel hücreleri vb.) aldım.
TÜSEB’in desteklediği ‘’Covid-19 Aşı Geliştirme Çalışmalarında Kullanılmak Üzere Antijenik Peptid/Proteinlerden Oluşan Yerli Bir Kütüphanenin Oluşturulması, Spesifik Antijenik Peptid/Proteinlerin Üretimi ve Immun Yanıtı Belirlenmiş Aşı Formülasyonu Eldesi’’ projesinde araştırmacı olarak görev almaktayım. Ayrıca ‘’İnsan Meme Kanserinin Farklı Suşlarına Karşı Tanıya Yönelik Hibridoma Teknolojisine Dayalı Poliklonal Antikorların Üretilmesi’’ adlı NAP Projesinde görev aldım. Şu anda da ‘’Visseral Leishmaniasise Karşı Polikaprolakton Temelli İmmünokemoterapötik Ajanları İçeren Nanopartiküler Taşıyıcı Sistemlerin Geliştirilmesi’’ adlı TÜBİTAK 1003 Projesinde ve ‘’Meme Kanserine Karşı Antijen Yüklü Polimerik Nanopartiküler Aşı Adaylarının Geliştirilmesi’’ adlı GAP Projesinde yer almaktayım. 2022 yılında Biruni Üniversitesinde öğretim görevlisi olarak çalışmaya başlamış olup hala bu kurumda görev yapmaktadır
Saygılarımla,
Murat IHLAMUR
05445240534
Dicle Üniversitesi Tıp Fakültesi’nden mezun olduktan sonra pratisyen doktor olarak çalıştım. Mersin Üniversitesi Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ve Genetik Anabilim Dalında 2003- 2006 tarihleri arasında yüksek lisans, 2007- 2012 tarihleri arasında ise doktora yaptım. 2017 yılından beri Mersin Üniversitesi Tıp Fakültesi Tıbbi Genetik AD’nda Dr. Öğr. Üyesi olarak çalışmaktayım
